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Abstract
Purpose: While the aetiology of rheumatoid arthritis (RA) remains unclear, many of the inflammatory components
are well characterised. For diagnosis and therapy evaluation, in vivo insight into these processes would be valuable.
Various imaging probes have shown value including dynamic contrast-enhanced (DCE) MRI and PET/CT using 18F-
fluorodeoxyglucose (18F-FDG) or tracers targeting the translocator protein (TSPO). To evaluate 18F-GE-180, a novel
TSPO PET tracer, for detecting and quantifying disease activity in RA, we compared 18F-GE-180 uptake with that of
18F-FDG and DCE-MRI measures of inflammation.
Methods: Eight RA patients with moderate-to-high, stable disease activity and active disease in at least one wrist
were included in this study (NCT02350426). Participants underwent PET/CT examinations with 18F-GE-180 and 18F-
FDG on separate visits, covering the shoulders and from the pelvis to the feet, including hands and wrists. DCE-MRI
was performed on one affected hand. Uptake was compared visually between tracers as judged by an experienced
radiologist and quantitatively using the maximum standardised uptake value (SUVmax). Uptake for both tracers was
correlated with DCE-MRI parameters of inflammation, including the volume transfer coefficient Ktrans using Pearson
correlation (r).
Results: PET/CT imaging with 18F-GE-180 in RA patients showed marked extra-synovial uptake around the affected
joints. Overall sensitivity for detecting clinically affected joints was low (14%). 18F-GE-180 uptake did not or only
weakly correlate with DCE-MRI parameters in the wrist (r = 0.09–0.31). 18F-FDG showed higher sensitivity for
detecting symptomatic joints (34%), as well as strong positive correlation with DCE-MRI parameters (SUVmax vs.
Ktrans: r = 0.92 for wrist; r = 0.68 for metacarpophalangeal joints).
Conclusions: The correlations between DCE-MRI parameters and 18F-FDG uptake support use of this PET tracer for
quantification of inflammatory burden in RA. The TSPO tracer 18F-GE-180, however, has shown limited use for the
investigation of RA due to its poor sensitivity and ability to quantify disease activity in RA.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune,
erosive arthropathy affecting 0.5–1% of the general
population [1]. If untreated, the condition can progres-
sively lead to severe damage of articular and periarticular
structures, significant disability, multiple comorbidities
and an overall reduction in life expectancy [2, 3]. Al-
though the aetiology of RA remains unclear, the com-
plex interaction of several proinflammatory cells,
including macrophages and mediators, is the basis of
disease pathogenesis. The net effect of these interactions
is synovial proliferation, sustained inflammation, in-
creased microvascular permeability and hyperaemia, ero-
sion of articular cartilage and bone, tissue matrix
degradation and eventual articular destruction [4, 5].
To quantify the inflammatory burden in RA non-
invasively, imaging using a variety of modalities includ-
ing magnetic resonance imaging (MRI) and positron
emission tomography computed tomography (PET/CT)
has been used. PET/CT with 18F-fluorodeoxyglucose
(18F-FDG) has been used to assess inflammation, as an
increase in 18F-FDG uptake is associated with immune
cell activation and recruitment. 18F-FDG uptake has
been shown to correlate with biochemical and clinical
markers of RA severity [6–14] and clinical outcome [15]
and has been used for the assessment of response to
therapy [15–22]. Nevertheless, as a tracer of glucose me-
tabolism, 18F-FDG is a non-specific marker of inflamma-
tion and is, e.g. in arthropathies also taken up by non-
inflammatory cells [9]. Similarly, dynamic contrast-
enhanced MRI (DCE-MRI) has been used to study RA
joint tissues and provides an established measure of local
severity of disease [23, 24]. Simpler contrast-enhanced
MRI endpoints [25, 26] are in fact used routinely for
assessing synovitis in intervention studies [23, 27, 28].
While more involved to implement, DCE-MRI is the
more sensitive of the methods and able to assess syn-
ovial perfusion/vascular permeability, vascular volume
and interstitial volume; all of which can be affected by
chronic inflammation. While DCE-MRI can provide
meaningful insight in the local inflammatory status in
RA, it can only measure a small field of view, e.g. a sin-
gle knee or wrist, and, like 18F-FDG, its signal is not spe-
cific for any cell type involved in RA. Both 18F-FDG PET
and DCE-MRI have been used previously to study joint
synovial inflammation in RA, but the two techniques
have not been compared in a single study.
Macrophages have a key role in RA, and in vivo quan-
tification would provide a valuable marker for tracking
disease activity and response to therapy. This has led to
the investigation of PET imaging with tracers targeting
translocator protein (TSPO), an outer-membrane mito-
chondrial protein ubiquitously expressed on activated
macrophages [29–32]. 18F-GE-180 [33] (flutriciclamide™;
GE Healthcare) is a novel TSPO ligand that has shown
improved specificity for TSPO compared to 11C-
PK11195 in preclinical studies [34, 35]. This tracer has
been previously evaluated for diagnosis and monitoring
of inflammation in neurological and neurodegenerative
pathologies, including multiple sclerosis, stroke and Alz-
heimer’s disease [34–36]. It has, however, not yet been
tested in rheumatic diseases such as RA. The aim of this
pilot study was therefore to identify and characterise in-
flammation in RA patients based on TSPO and abnor-
mal glucose metabolism with 18F-GE-180 and 18F-FDG
PET/CT, using DCE-MRI to correlate perfusion-based
measures of inflammation with tracer uptake for both
tracers. This study used an adaptive design with an in-
terim futility analysis to allow poor initial observations
with 18F-GE-180 imaging to trigger early termination.
Materials and methods
Patient population
Nine patients were recruited by advertisement and from
the outpatient population of Addenbrooke’s Hospital,
Cambridge, UK. For inclusion, patients had to fulfil ei-
ther the 1987 American College of Rheumatology defin-
ition or the 2010 American College of Rheumatology/
European League Against Rheumatism (ACR/EULAR)
classification criteria for RA [37]. These RA patients
needed to have stable disease with moderate-to-high ac-
tivity as defined by a disease activity score of 28 joints
[38], using the erythrocyte sedimentation rate (DAS28-
ESR), of ≥ 3.2 at screening and at least one painful or
swollen wrist joint as assessed by a rheumatologist. Pa-
tients receiving treatment with biologics were excluded
from the study. One patient was withdrawn at the dis-
cretion of the investigator (DF) following the incidental
finding of a lung lesion that required separate follow-up
which precluded continuation in the study, leaving eight
patients for analysis.
The study (trial NCT02350426, GSK study 201659)
was approved by a National Research Ethics Committee
(REC no 14/SC/1405) and the Administration of Radio-
active Substances Advisory Committee (ARSAC), UK.
All subjects gave written informed consent before par-
ticipation in the study.
Clinical evaluation
Joint swelling and tenderness were assessed for all joints
included in the DAS28 score. Laboratory markers of in-
flammation, including ESR and C-reactive protein
(CRP), were also measured. Joint scores, ESR and a pa-
tient global health assessment were used to calculate the
DAS28-ESR score, which was assessed at screening to
determine inclusion and again at both imaging visits. All
clinical evaluations were performed by a rheumatologist
at screening and by a specialist nurse trained in joint
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assessment at the study visits. In addition, the joint as-
sessments permitted a binary classification into symp-
tomatic (swollen and/or tender) and asymptomatic
joints. Given the effect of the Ala147Thr polymorphism
on TSPO-binding affinity for 18F-GE-180, all participants
were tested for presence of this polymorphism, and
individuals with predicted low-binding affinity were
excluded from the study [39]. Medical history, demo-
graphics and concomitant medication information were
also collected.
Imaging protocol
PET/CT: Examinations were undertaken on a GE Dis-
covery 690 PET/CT (GE Healthcare; Waukesha, WI),
Addenbrooke’s Hospital, UK. Participants underwent
two PET/CT scans, one with 18F-FDG (Alliance Medical,
UK) and the other with 18F-GE-180 (GE Healthcare,
Amersham, UK), ordered randomly, with the second
scan occurring 1–15 days after the first scan (median: 8
[range: 6–15] days). PET scans involved intravenous ad-
ministration of 159 ± 7MBq 18F-FDG or 189 ± 6MBq
18F-GE-180. Administration of both tracers was followed
by an uptake period of 60 min (median: 60.2 [range:
59.4–70.2] min). A low-dose CT (120 kVp 30 mA, 1.375
pitch) was acquired immediately prior to each PET ac-
quisition for attenuation correction and anatomical lo-
calisation. PET imaging of the lower body, extending
from the pelvis to the bottom of the feet, included 8–10
axial bed positions; 5 min/bed position. Subjects were
imaged in the supine position with arms down to ensure
coverage of the hand and wrist area, with hands lightly
bandaged to acrylic positioning devices to allow for fair
comparison between subjects and imaging modalities. A
separate 5-min single-bed acquisition of the shoulder area
was performed starting 120 min (median: 119.6 [range:
119.1–120.6] min) post tracer administration. Prior to 18F-
FDG injection, patients were required to fast for at least 6
hr. Fasted blood glucose concentration was tested in all
participants to ensure levels were below 7 mmol/L.
Emission data were reconstructed into a 256 × 256 ×
47 matrix with 2.7 × 2.7 × 3.27 mm voxels, using time-
of-flight ordered subsets-expectation maximisation
(TOF-OSEM) with 4 iterations and 24 subsets. Correc-
tions were applied for attenuation, scatter, randoms,
dead time, sensitivity, normalisation and isotope decay,
together with a 6-mm full width at half maximum
Gaussian filter post reconstruction.
MRI: Imaging of the right wrist (which was deemed
the most affected in all subjects’ clinical assessments)
was performed on a 3 T MR system (MR750, GE Health-
care; Waukesha, WI), Addenbrooke’s Hospital, Cam-
bridge, UK, using an 8-channel knee coil. Patients were
scanned in the prone position, with the arm of the af-
fected hand extending upwards above their head. The
hand was positioned in the centre of the coil, with the
coil in the centre of the magnet to ensure good signal in
both the wrist and metacarpophalangeal joints. The
hand was lightly bandaged to the same positioning de-
vice used during PET/CT scanning and placed inside the
coil to minimise motion during scanning.
The imaging protocol included a coronal pre-contrast
fat-suppressed (FS) T1-weighted 3D spoiled gradient
echo (3D SPGR) acquisition for radiological assessment
as well as for shape modelling and ROI definition. This
sequence was repeated post-contrast at the end of the
imaging session. For DCE-MRI, 3D variable flip angle
SPGR acquisitions were acquired first to allow baseline
T1-mapping, followed by a 7-minute dynamic 3D SPGR
sequence, during which gadolinium (Gd) contrast agent
was administered. A dose of 0.1 mmol/kg body weight
of gadobutrol (Gadovist, Bayer Schering Pharma, Berlin,
Germany) was injected using a power injector, followed
by a 25mL flush of saline. Both volumes were injected
at 3.0 mL/s, with injection of the contrast agent at the
sixth measurement of the dynamic series. Pulse se-
quence parameters are described in Table 1. Total scan
time was limited to < 30 min to keep the potential for
patient discomfort to a minimum.
Image quantification and scoring
For both PET tracers, both qualitative and quantitative
evaluations were performed by an experienced radiolo-
gist (NP). For qualitative evaluation, joints were
inspected visually with uptake compared to uptake in
adjacent subcutaneous tissue and bone (marrow). Up-
take was categorised using a three-point scale: normal,
possibly abnormal and definitely abnormal. Quantitative
Table 1 MRI scanning parameters for structural and DCE-MR
imaging
3D SPGR + FS PRE/POST-
Gd
3D DCE-MRI
Scan plane Coronal Coronal
TE (ms) 8.3 1.2
TR (ms) 30 3.5
Flip angles (deg) 30 6, 2, 14 for T1-
mapping,
14 for dynamic series
FOV (cm) 18 18
Phase FOV 0.75 0.75
Slice thickness
(mm)
1.5 1.5
Slices acquired 40 40
Measurements - 8 for T1-mapping,
54 for dynamic series
Acquisition matrix 512 × 288 180 × 136
Saturation Fat suppression -
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analysis involved calculation of maximum standardised
uptake values (SUVmax), normalised to body weight,
identified as the maximum inside a sphere encompassing
the joint, while making sure that the location of the
maximum was inside the synovium. Joints incorporated
in the DAS28 calculation, including the shoulders,
wrists, metacarpophalangeal and proximal interphalan-
geal joints and knees, as well as the distal interphalan-
geal joints the hips and ankles, were evaluated. The
elbows were not imaged as part of this study, giving 38
joints evaluated per patient qualitatively and quantita-
tively. The hips of one patient could not be evaluated,
and one hip of a single subject was excluded from evalu-
ation as it had been replaced by a joint prosthesis. All as-
sessments were performed with the reviewer blinded to
clinical and other imaging data.
For the DCE-MRI analysis, all images were centrally
checked for image quality with any images suffering
from operator error or image artefacts discarded. Re-
gions of interest of wrist and metacarpophalangeal joint
synovial spaces were defined on the pre-contrast 3D
SPGR+FS images using active appearance models [40]
which were previously built from an independent train-
ing set of subjects (RA patients and healthy volunteers).
Pharmacokinetic analysis of DCE-MRI data utilised the
standard Tofts model [41] for the calculation of the vol-
ume transfer coefficient, Ktrans, as previously described
[23]. Also, a simpler data-driven model was fitted to the
DCE-MRI time series to yield estimates for the initial
rate of enhancement (IRE) and maximal enhancement
(ME). The volume of the enhancing pannus (VEP) was
calculated from the difference between the pre- and
post-contrast 3D SPGR+FS images to identify regions of
enhancement in the joint and normalised to the total
synovial volume (Vtotal) as VEP/Vtotal. Scanner specific
T1 correction of the DCE-MRI data was also performed
using phantom data, as described previously [23].
3D DCE-MRI parametric maps were evaluated in an
ROI based on the VEP for each joint of interest, with
non-enhancing voxels excluded from both models. Vox-
elwise parameter estimates were averaged for Ktrans, IRE
and ME for each joint.
Statistical analysis
This was an exploratory study and therefore there were
no formal sample size calculations. For qualitative ana-
lysis, clinical symptoms and tracer uptake were cross-
tabulated. Treating symptoms as positive/negative (P/N)
and tracer increase as a detection test with true/false (T/F)
labels, commonly defined performance measures were com-
puted as follows: sensitivity = TP / (TP + FN), specificity =
TN / (TN + FP), positive predictive value = TP / (TP + FP)
and negative predictive value = TN / (TN + FN). Lastly, the
agreement between visual scores of both tracers was com-
piled in a confusion matrix.
To evaluate 18F-FDG and 18F-GE-180 for the assess-
ment of disease severity, quantitative measures of tracer
uptake in the wrist and metacarpophalangeal joints were
correlated with DCE-MRI measures using Pearson cor-
relation (r). Primarily, our analysis focused on correla-
tions with Ktrans, as a marker of local severity of disease,
but also included other DCE-MRI parameters (VEP;
VEP/Vtotal; IRE; ME).
All analyses were performed as available-case analysis
to deal with sporadic missing values caused by failure of
the DCE-MRI model to converge or clinical assessments
that could not be performed. Analyses were performed
using SAS software (Version 9.4 m3, SAS Institute Inc.,
Cary, NC, USA). Data are presented as number (%),
mean ± standard deviation (SD) or median [range] as
appropriate.
Results
Demographics
The mean age of the subjects was 54 ± 12.1 years. Three of
the patients were female (38%). The mean body mass index
(BMI) of the subjects was 28.4 ± 4.6 kg/m2. Further demo-
graphic information is given in Table 2, which is generated
post hoc to only summarise the imaging population.
Table 2 Participant demographics
Overall (N = 8)
Age (years) 54 (12.1)
Sex
Female 3 (38)
Male 5 (63)
BMI (kg/m2) 28.4 (4.6)
Height (m) 1.75 (0.08)
Weight (kg) 85.7 (9.4)
Race
White-White/Caucasian/European Heritage 8 (100)
DAS28-ESR 5.4 (0.9)
Tender joints median [range] 14.5 [8–27]
Swollen joints median [range] 3.5 [2–9]
ESR (mm) 17.5 (11.1)
CRP (mg/L) 7.3 (8.5)
Median [range] 3.0 [1.5–24.5]
Binding affinity for TSPO
Mixed affinity 4 (50)
High affinity 4 (50)
Values expressed as mean (SD) or n (%) as appropriate unless indicated
differently. Values determined at screening. BMI indicates body mass index,
DAS disease activity score, ESR erythrocyte sedimentation rate, CRP C-reactive
protein, TSPO translocator protein, SD standard deviation
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Qualitative analysis
Observations on the 18F-GE-180 images include substan-
tial but variable activity in muscle and vasculature,
which was more pronounced than for 18F-FDG. There
was also prominent activity within the marrow. In par-
ticular, in one patient there was marked activity in the
marrow extending from the spine to the knees and prox-
imal tibiae (Fig. 1). This uptake corresponded with simi-
lar but less avid uptake on the 18F-FDG scan and was
suggestive of a reactive marrow. In general, 18F-GE-180
uptake in clearly affected joints was much less than ex-
pected and often only subtly raised against background.
Example images are displayed in Fig. 1 a–c. The variabil-
ity in appearance made it difficult to suggest an appro-
priate reference tissue for this tracer.
A definite increase in the visual score was observed for
18F-FDG uptake in 46 (15%) joints as compared with 11
(4%) joints for 18F-GE-180. Possible increase was identified
in 28 (9%) and 22 (7%) joints for 18F-FDG and 18F-GE-
180, respectively. When constrained to joints included in
the clinical assessment of the DAS28 score, most of the
symptomatic joints did not show increased scores for ei-
ther tracer on visual inspection, even when grouping ‘def-
inite’ and ‘possible’ increase categories. Summarised
results for these joints are shown in Table 3 (post hoc ana-
lysis). Performance measures including specificity and
positive and negative predictive values of visual scores for
both tracers are listed in Table 4 (post hoc analysis).
Sensitivity for detecting symptomatic joints was 34% for
18F-FDG and 14% for 18F-GE-180.
There was a fair correspondence between visual scores
for both tracers, shown in Table 5. While most joints
were classified as ‘normal’ for both tracers, the majority
of joints that showed increased 18F-GE-180 uptake also
showed increased 18F-FDG uptake. Conversely however,
only a minority of joints that showed increased 18F-FDG
uptake also showed increased 18F-GE-180 uptake.
Quantitative analysis
Correlations between PET and DCE-MRI measures in
the hand showed a strong correlation between 18F-FDG
SUVmax in the wrist and DCE-MRI K
trans as shown in
Fig. 2a (post hoc analysis) and reflected in a Pearson cor-
relation coefficient (r) of 0.92. The same analysis for 18F-
GE-180 showed no correlation (r = 0.15), Fig. 2b (post
hoc analysis). Correlations for other DCE-MRI parame-
ters were comparable for both tracers and are listed in
the first columns of Table 6 (post hoc analysis). Correla-
tions for metacarpophalangeal joints showed slightly
weaker correlations for 18F-FDG (r = 0.68 for Ktrans)
than for the wrist, and weak correlations for 18F-GE-180
(r = 0.38 for Ktrans), shown in the last columns of Table 6
(post hoc analysis). Figure 3 (post hoc analysis) shows an
example correlation plot for the metacarpophalangeal
joints for correlation between Ktrans and 18F-FDG SUVmax
as a representative illustration of the distribution of the
measurements.
Discussion
In this exploratory pilot study on combined molecular
imaging techniques and DCE-MRI for RA, we found
strong positive correlations (range: r = 0.7–0.9) between
severity of disease as measured by DCE-MRI parameters
and glucose metabolism measured with 18F-FDG across
hand and wrist joints. For the novel TSPO ligand 18F-
GE-180, these correlations were weak (range: r = 0.1–0.5).
When visually identifying clinically symptomatic joints, a
comparison between 18F-FDG and 18F-GE-180 suggested
a marginally higher specificity in detecting RA pathology
for the TSPO ligand (73% and 87%, respectively) but with
a lower sensitivity (34% and 14%, respectively). The poor
ability to identify symptomatic joints or disease activity in
symptomatic joints suggests a poor applicability of 18F-
GE-180 for disease quantification in RA.
Considering the systemic nature of RA and that
macrophage synovial infiltration can be present without
clinically active rheumatoid arthritis [42, 43], it was
hypothesised that 18F-GE-180 would demonstrate better
sensitivity than 18F-FDG in identifying joints with subclin-
ical synovial tissue inflammation. Through its mechanistic
involvement by binding to the macrophages that are piv-
otal in the pathogenesis of RA, it was also hypothesised
that 18F-GE-180 would offer increased specificity to in-
flammation against, e.g. osteoarthritic degeneration.
Earlier reports on the use of TSPO PET tracers in RA
indeed suggest applicability in imaging of the inflamed
synovium in RA. Van der Laken et al. [29] previously
showed higher expression of TSPO with 11C-PK11195 in
RA patients with severe synovial swelling of the knee
compared to patients with mild swelling of the knee,
correlating with TSPO and the macrophage marker
CD68 on immunohistochemistry. In addition, tracer up-
take in contralateral uninflamed knee joints of these pa-
tients was significantly higher than in uninflamed joints
of control patients without inflammatory joint disease,
suggesting the ability to demonstrate presence of sub-
clinical disease activity. More specifically, Narayan et al.
[32] used autoradiography and PET imaging with PBR-
28 ligands in patients with RA and healthy controls and
found elevated TSPO expression by fibroblast-like syno-
viocytes and activated macrophages in the synovium of
RA patients. In our study, we explored the utility of 18F-
GE-180, a TSPO tracer with higher selectivity for TSPO
than 11C-PK11195 [33], for the quantification of joint in-
flammation in RA as a potential tool for evaluating re-
sponse to (novel) therapies in RA. This is the first study
testing this novel tracer for a non-neurological indica-
tion, and the relevant scanning parameters were selected
de Groot et al. EJNMMI Research           (2019) 9:113 Page 5 of 11
Fig. 1 Representative imaging. a demonstrates maximum intensity projections (MIPs) of two patients imaged with 18F-FDG and 18F-GE-180. The
two left images are of a patient who has increased right knee joint uptake with 18F-FDG, not seen with 18F-GE-180, which is also demonstrated
on axial and coronal fused images in b. The images with 18F-GE-180 demonstrate a typical pattern of physiological uptake with marrow uptake in
the proximal femurs and diffuse muscle uptake. The two right images of Fig. a are of a separate patient who demonstrates marked uptake within
the marrow down to the proximal tibiae with 18F-GE-180. A similar but less intense uptake is seen with 18F-FDG and is presumed related to a
reactive marrow. c are coronal and sagittal images of a patient with increased uptake in the medial aspects of both knee joints which is much
more marked with 18F-FDG, compared to 18F-GE-180. The 18F-GE-180 images also demonstrate increased muscle and marrow uptake. The scale
on all figures is SUV (g/mL)
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on the basis of preclinical data [35] and discussions with
GE Healthcare where initial human data were shown.
The chosen time window for the study is consistent with
published work in the brain [44–46], which indicates
time-activity curves reaching a plateau after ~ 40–45
min post-injection and good agreement between SUV
ratio and Logan distribution volume ratio for time points
later than 60min.
This exploratory study used an adaptive design, offer-
ing an interim futility analysis. While the original target
for this study was the inclusion of 20 patients, the unsat-
isfactory performance of 18F-GE-180, as shown in the
imaging results presented here, led to early termination
of the study.
The strengths of this study are the side-by-side com-
parison of 18F-FDG and DCE-MRI to assess synovitis in
RA for the first time, the use of a well-characterised pa-
tient cohort and the evaluation of a novel TSPO tracer
to image macrophage burden. The limitations are the re-
liance on imaging measures to determine synovial in-
flammation without having the capability to confirm this
by tissue analysis, the absence of a control-group with-
out RA and the limited sample size. A consequence of
the early termination of this study was that only two
participants underwent the optional dynamic PET im-
aging using 18F-GE-180, with both data sets non-
analysable for technical reasons. Unavailability of dy-
namic imaging data thus prevented us to investigate
pharmacokinetics and to verify static imaging
parameters.
In RA, clinically non-inflamed joints can show signs of
inflammation when analysing the synovial tissue [43].
Although not confirmed by tissue analysis, in our study
27% and 13% of asymptomatic, clinically non-inflamed
joints showed visible signs of inflammation on18F-FDG
and 18F-GE-180 imaging, respectively. The poor
sensitivity measures observed in this study highlight the
failure of both tracers to detect a substantial portion of
clinically symptomatic joints (Table 4).
The reported sensitivity of 18F-FDG for detecting in-
flammatory arthritis, as based on clinical assessment,
varies between 56% and 77% [47]. In a study of 21 pa-
tients with active RA, positivity using 18F-FDG was
found in 63% of joints, whereas 75% and 79% were posi-
tive for swelling and tenderness analysis, respectively [6].
The 18F-FDG sensitivity found in our study of 34% was
lower. While the mean DAS28 score of 5.4 is representa-
tive for an RA patient population with moderate-to-high
disease activity, the median CRP value found in our
study was relatively low (3.0 (range: 1.5–24.5) mg/L)
when compared to values found in the literature [6, 7,
48, 49]. It is possible that the low CRP levels in our
study reflect a population with milder systemic inflam-
matory activity, which could in part explain the overall
lower level of 18F-FDG sensitivity.
The difference in the number of symptomatic joints
and joints showing synovial uptake of 18F-FDG may be
explained by the difference in definitions of ‘abnormal
18F-FDG uptake’. In this study, abnormality was defined
by comparison with adjacent structures, whereas studies
reported in the literature used comparisons with refer-
ence tissues, such as the liver and brain [13, 48]. In our
study, some joints were not classified as abnormal des-
pite having uptake greater than the liver because uptake
was considered spurious due to, e.g. spillover of uptake
from adjacent structures (e.g., bone marrow) and in-
creased noise from joints being at the edge of the field
of view. In addition, abnormal uptake in our study was
defined as synovial uptake, while uptake in associated
structures such as musculotendinous junctions was dis-
regarded. It is possible that uptake in these adjacent
Table 3 Cross-tabulation of PET-CT visual score and clinical status
18F-FDG visual score 18F-GE-180 visual score
Normal Increased Total Normal Increased Total
Symptomatic joints 74 38 112 100 16 116
Asymptomatic joints 70 26 96 80 12 92
Total 144 64 208 180 28 208
Joints that were swollen and/or tender were regarded symptomatic. Joints in DAS28 examination were included; elbows were not imaged
Table 4 PET-CT visual score and clinical status, performance at
identifying symptomatic joints
18F-FDG 18F-GE-180
Sensitivity (%) 34 14
Specificity (%) 73 87
Positive predictive value (%) 59 57
Negative predictive value (%) 49 44
Table 5 Agreement between visual uptake scores of both tracers
18F-GE-180
normal increased total
18F-FDG normal 223 6 229
increased 47 27 74
total 270 33 303
Joints included in the DAS28, plus the distal interphalangeal joints, the hips,
knees and ankles were evaluated. The elbows were not imaged. See Appendix
for note on corrected number of joints included
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Fig. 2 Correlation between Ktrans and SUVmax in wrist joints for
18F-FDG (a) and 18F-GE-180 (b)
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structures of a joint could represent features that clinic-
ally may be assessed as a symptomatic (swollen and/or
tender) joint.
In our study, 18F-FDG PET quantified inflammatory
disease activity well when using DCE-MRI as compari-
son. This observation strengthens confidence in both
imaging probes but, in combination with the poor
correlation found between markers of systemic
inflammation and clinical symptomatology, also high-
lights the distinct aspects of disease probed clinically
and through imaging. The results of our study suggest
that 18F-FDG PET as well as DCE-MRI can add robust
information on disease activity to the clinical evaluation
of joints.
The data from our study are in broad agreement with
some published preclinical studies [50], but even though
previous reports in RA with 11C-PK11195 and more re-
cently PBR-28 ligands have shown more encouraging re-
sults [29, 32], our results do not support use of 18F-GE-
180 in the RA population investigated. Without biopsy
data, it is not possible to know whether the low uptake
of 18F-GE-180 was the result of low TSPO expression in
the synovial tissue perhaps due to a less inflammatory
population or poor performance by the tracer.
Conclusion
In this study, 18F-FDG PET-CT visual scores showed
limited ability in identifying symptomatic joints in RA,
but quantitative interpretation revealed a high agreement
with DCE-MRI measures in quantifying disease activity
in the hands. While 18F-GE-180 PET-CT might be
slightly more specific at detecting symptomatic joints in
RA, its poor sensitivity and ability to quantify synovial
inflammation in RA will mostly preclude further use of
the tracer in this disease.
Fig. 3 Correlation between Ktrans and SUVmax in metacarpophalangeal joints for
18F-FDG
Table 6 Pearson correlation coefficients for correlations
between DCE-MRI parameters and SUVmax for
18F-FDG (A) and
18F-GE-180 (B)
Wrist joint MCP joints
A 18F-FDG
Ktrans 0.92 0.68
VEP/Vtotal 0.90 0.82
IRE 0.92 0.71
ME 0.92 0.70
B 18F-GE-180
Ktrans 0.15 0.38
VEP/Vtotal 0.31 0.47
IRE 0.13 0.36
ME 0.09 0.29
MCP indicates metacarpophalangeal
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Appendix
Due to an acquisition problem, the hips of one patient
could not be evaluated, but they were erroneously scored
as ‘normal’ on 18F-GE-180. As a result, the normal-
normal cell in Table 5 should therefore read 221, instead
of 223. Percentages for joints with uptake for both
tracers mentioned in the text are unchanged.
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